Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results, according to analysts at Bank of America. They noted that the 2025-2026 vaccine season is winding down, and the company's litigation risks are largely in the past following a $950 million upfront payment in the first quarter, though analysts note the potential for up to $1.3 billion in additional payments depending on the outcome of an ongoing legal appeal.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

This company soared into the spotlight with its first product a few years ago. But in recent years, the company's earnings and stock price declined.

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026. Moderna's presentation, "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults," details an exploratory, post-hoc analysis assessing the safety and immunogenicity of mRNA-1010 in adults 50 years and older following prior seasonal influenza vaccination with mRNA-1010 or a licensed egg-based influenza vaccine.

My previous recommendation of Moderna didn't work out so well, because COVID sales have declined over the last several years. Spikevax 2024 sales reached only $3.1B, and RSV sales were a major disappointment at $25M, failing to offset COVID-19 declines. Despite a 40% YoY revenue drop to $1.9B in 2025, MRNA maintains robust liquidity with $8.1B in cash/investments and a conservative 0.151 debt-to-equity ratio.

In the closing of the recent trading day, Moderna (MRNA) stood at $49.2, denoting a -1.66% move from the preceding trading day.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.

SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.

Moderna (MRNA) concluded the recent trading session at $49.56, signifying a -7.49% move from its prior day's close.